PCSA (Processa Pharmaceuticals) Short Interest


PCSA Processa Pharmaceuticals Inc PCSA
28 GF Score
Price $2.16
! 1 Warning Sign
View Full Analysis

What is Processa Pharmaceuticals Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

PCSA vs ELAB, MBIO, DRMA: Short Interest Comparison

For the Biotechnology subindustry, Processa Pharmaceuticals's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Processa Pharmaceuticals Short Interest vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Processa Pharmaceuticals's Short Interest distribution charts can be found below:

* The bar in red indicates where Processa Pharmaceuticals's Short Interest falls into.


PCSA
28GF Score
Processa Pharmaceuticals Inc PCSA
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Processa Pharmaceuticals Business Description

Address 601 21st Street, Suite 300, Vero Beach, FL, USA, 32960
Processa Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on utilizing its regulatory science approach in the development of Next Generation Chemotherapy (NGC) oncology drug products. The company's strategic prioritization is to advance its pipeline of NGC proprietary small-molecule oncology drugs. The NGC products are new chemical entities, but the company works by changing the metabolism, distribution, and/or elimination of already FDA-approved cancer drugs or their active metabolites while maintaining the mechanism of how the drug kills cancer cells. The four NGC treatments in its pipeline are PCS6422 (also referred to as NGC-Cap), PCS11T, also referred to as NGC-Iri, is an analog of SN38, and PCS11T, PCS12852, and PCS499.
28GF Score

Get the complete analysis for PCSA

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.16
Price